LDL-C or apoB as the best target for reducingcoronary heart disease: should apoB be implemented into clinical practice?

Bibliography

• Grundy SM, Cleeman JI, Merz CNB et al.: Implication of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227–239 (2004).
   Google Scholar
• Graham J, Atar D, Borch-Johnsen K et al.: European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 28, 2375–2414 (2007).
   Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366, 1267–1278 (2005).
   Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators: Efficacy of cholesterollowering treatment in 18,686 people with diabetes in 14 randomized trials of statins: a meta-analysis. Lancet 371, 117–125 (2008).
   Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047–1053 (2004).
   Google Scholar
• Fruchart JC, Sacks F, Hermans MP et al.: The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol. 102, 1K–34K (2008).
   Google Scholar
• Sniderman AD, Furberg CD, Keech A et al.: Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361, 777–780 (2003). n Summarizes the evidence comparing the utility of apoB versus the cholesterol parameters to identify those at increased risk of vascular disease and to judge the adequacy of statin therapy.
   Google Scholar
• Sniderman AD, Lamarche B, Tilley J et al.: Hypertriglyceridemic hyperapoB in Type 2 diabetes. Diabetes Care 25, 579–582 (2002)
   Google Scholar
• Demonstrates that more than one in five Type 2 diabetic patients had hypertriglyceridemic hyper-apoB, which is characterized by hypertriglyceridemia, marked elevation of LDL particle numbers, small dense LDL and low HDL, a constellation of abnormalities that is associated with markedly accelerated atherogenesis and therefore justifies intensive medical therapy.
   Google Scholar
• Sniderman AD, Faraj M: Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome. Curr. Opin. Lipidol. 18, 633–637 (2007)
   Google Scholar
• Demonstrates that both the apoB:apoA-I ratio and apoB are tightly linked to the metabolic syndrome. Moreover, apoB associates more closely with inflammatory markers and insulin resistance than triglyceride and all cholesterol markers.
   Google Scholar
• Cromwell WC, Otvos JD, Keynes MJ et al.: LDL particle number and risk of future cardiovascular disease in Framingham Offspring Study: implications for LDL management. J. Clin. Lipidol. 1, 583–592 (2007)
   Google Scholar
• In this large community-based sample, LDL particles assessed by nuclear magnetic resonance was a more sensitive indicator of low cardiovascular disease risk than either LDL?C or non-HDL?C, suggesting a potential clinical role for LDL particles as a goal of LDL management.
   Google Scholar
• Jeyarajah EJ, Cromwell WC, Otvos JD: Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin. Lab. Med. 26, 847–870 (2011).
   Google Scholar
• Packard CJ: Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr. Opin. Lipidol. 17, 412–417 (2011).
   Google Scholar
• Skalen K: Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417(6890), 750–754 (2002).
   Google Scholar
• Khalil MF, Wagner WD, Goldberg IJ: Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24, 2211–2218 (2004).
   Google Scholar
• St Pierre AC, Cantin B, Dagenais GR et al.: Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler. Thromb. Vasc. Biol. 25, 553–559 (2005).
   Google Scholar
• Koba S, Yokota Y, Hirano T et al.: Small LDL?cholesterol is superior to LDL?cholesterol for determining severe coronary atherosclerosis. J. Atheroscler. Throm. 15, 250–260 (2008).
   Google Scholar
• Jungner I, Sniderman AD, Furberg C et al.: Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? Am. J. Cardiol. 97, 943–946 (2011).
   Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486–2509 (2001).
   Google Scholar
• Sniderman AD, St-Pierre A, Cantin B et al.: Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am. J. Cardiol. 91, 1173–1177 (2003)
   Google Scholar
• Examines the correlation and concordance between non-HDL?C and apoB.
   Google Scholar
• Sniderman AD, Hoque JC, Bergeron J, Gagn’ C, Couture P: Non-HDL cholesterol and apoB in dyslipidemia. Clin. Sci. 114, 149–155 (2008)
   Google Scholar
• Indicates that there is substantial variance of apoB for given values of non-HDL?C in many dyslipidemic subjects. It follows that correlation is not sufficient as a sole judge of equivalence of laboratory parameters.
   Google Scholar
• Lamarche B, Moorjani S, Lupien PJ et al.: Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a five year follow-up of men in Québec Cardiovascular Study. Circulation 94, 273–278 (1996).
   Google Scholar
• Ridker PM, Rifai N, Cook NR et al.: Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294, 326–333 (2005).
   Google Scholar
• Pischon T, Girman CJ, Sacks FM et al.: Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112, 3375–3383 (2005).
   Google Scholar
• Walldius G, Jungner I, Holme I et al.: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358, 2026–2033 (2001)
   Google Scholar
• In a large study of 175,553 individuals, apoB and the apoB:apoA-I ratio were strongly and positively related to increased risk of fatal myocardial infarction in men and women. In multivariate analysis, apoB was a stronger predictor of risk than LDL?C in both sexes.
   Google Scholar
• St-Pierre AC, Cantin B, Dagenais GR et al.: Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. Am. J. Cardiol. 97, 997–1001 (2011).
   Google Scholar
• Benn M, Nordestgaard BG, Jensen GB et al.: Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler. Thromb. Vasc. Biol. 27, 661–670 (2007).
   Google Scholar
• Chien KL, Hsu HC, Su TC et al.: Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese. J. Lipid Res. 48, 2499–2505 (2007).
   Google Scholar
• Sierra-Johnson J, Fisher RM, Romero?Corral A et al.: Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multiethnic US population. Eur. Heart J. 30, 710–717 (2011).
   Google Scholar
• Mora S, Otvos JD, Rifai N et al.: Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 119, 931–939 (2011).
   Google Scholar
• Thompson A, Danesh J: Association between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J. Intern. Med. 259, 481–492 (2011).
   Google Scholar
• Contois JH, McConnell JP, Sethi AA et al.: Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin. Chem. 55, 407–419 (2011)
   Google Scholar
• Comprehensive review of studies demonstrating that apoB is a better measure of circulating LDL particle numbers and is a more reliable indicator of risk than LDL?C. This statement supports addition of apoB in the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III and other guidelines in the USA.
   Google Scholar
• Talmud PJ, Hawe E, Miller GJ et al.: Non-fasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler. Tromb. Vasc. Biol. 22, 1918–1923 (2002).
   Google Scholar
• Blake GJ, Otvos JD, Rifai N et al.: Low density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106, 1930–1937 (2002).
   Google Scholar
• Otvos JD, Collins D, Freedman DS et al.: Low density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affair High-Density Lipoprotein Intervention Trial. Circulation 113, 1556–1563 (2011).
   Google Scholar
• Rosenson RS, Otvos JD, Freedman DS: Relations of lipoprotein subclass levels and low-density lipoprotein size to progression in coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-1) trial. Am. J. Cardiol. 90, 89–94 (2002).
   Google Scholar
• El Harchaoui K, van der Steeg WA, Stroes ESG et al.: Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women. J. Am. Coll. Cardiol. 49, 547–553 (2007).
   Google Scholar
• The Emerging Risk Factors Collaboration: Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993–2000 (2011).
   Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G et al.: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 115, 450–458 (2007).
   Google Scholar
• Krauss RM, Siri PW: Metabolic abnormalities: triglyceride and low density lipoprotein. Endocrinol. Metab. Clin. North Am. 33, 405–415 (2004).
   Google Scholar
• Kathiresan S, Otvos JD, Sullivan LM et al.: Increased small low-density lipoprotein particle number. A prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113, 20–29 (2011)
   Google Scholar
• Small LDL particle numbers (measured by the nuclear magnetic resonance method) and apoB concentration increased from zero to five metabolic syndrome traits, while there was no change in LDL?C levels in those with one to five symptoms.
   Google Scholar
• Han JH, Park HS, Kim JA, Kim SM: Apolipoprotein B is a better marker than non-HDL?cholesterol for the metabolic syndrome in Koreans. Atherosclerosis 197, 333–338 (2008).
   Google Scholar
• Williams K, Tchernof A, Hunt K et al.: Diabetes, abdominal adiposity, and atherogenic dyslipoproteinemia in women compared to men. Diabetes 57, 3289–3295 (2008)
   Google Scholar
• Demonstrates that apoB, and not LDL?C or non-HDL?C, is most different between nondiabetic and diabetic women. It explains the marked increase in cardiovascular risk when women become diabetic.
   Google Scholar
• Veerkamp MJ, de Graaf J, Stalenhoef AFH: Role of insulin resistance in familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 25, 1026–1031 (2005)
   Google Scholar
• Supports the concept of a genetic origin of high apoB and small dense LDL in familial combined hyperlipidemia, which is modulated by insulin resistance and obesity.
   Google Scholar
• Veerkamp MJ, de Graaf J, Hendriks JCM et al.: A nomogram to diagnose familial combined hyperlipidemia based on results of a 5-year follow-up study. Circulation 109, 2980–2985 (2004)
   Google Scholar
• The diagnosis of familial combined hyperlipidemia is best predicted by absolute apoB levels combined with triglyceride and total cholesterol levels adjusted for age and gender and can be accurately calculated by a nomogram.
   Google Scholar
• Gotto AM Jr, Whitney E, Stein EA et al.: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101, 477–484 (2000)
   Google Scholar
• On-treatment apoB and especially the apoB:AI ratio may be a more accurate predictor of risk for the first acute major coronary event than LDL?C.
   Google Scholar
• Simes RJ, Marschner IC, Hunt D et al.: Relationship between lipid levels and clinical outcomes in the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 105, 1162–1169 (2002).
   Google Scholar
• Roeters van Lennep JE, Westerveld HT, van Lennep HW et al.: Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler. Thromb. Vasc. Biol. 20, 2408–2413 (2000).
   Google Scholar
• Kastelein JJP, van der Steeg WA, Holme I et al.; for the TNT and IDEAL Study Groups: Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117, 3002–3009 (2008)
   Google Scholar
• In patients receiving statin therapy, on-treatment levels of non-HDL?C and apoB were more closely associated with cardiovascular outcome than levels of LDL?C. Among the ratios evaluated, apoB:A-I showed the strongest relationship.
   Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN et al.: Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controled trial. Lancet 364, 685–696 (2004).
   Google Scholar
• Charlton-Menys V, Betteridge DJ, Colhoun H et al.: Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin. Chem. 55, 473–480 (2011)
   Google Scholar
• Demonstrates that in diabetic patients the apoB concentration provides a more consistent goal for statin treatment than the LDL?C or non-HDL-C concentration.
   Google Scholar
• Sniderman AD: Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL lowering therapy: implications to clinical practice. J. Clin. Lipidol. 2, 36–42 (2008)
   Google Scholar
• Demonstrates that statin therapy lowers LDL?C and non-HDL?C more and to lower population percentile levels than apoB. Thus, many patients treated to LDL?C or non-HDL?C targets remain at high risk owing to high levels of atherogenic particles.
   Google Scholar
• Barter PJ, Ballantyne CM, Carmena R et al.: ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J. Intern. Med. 259, 247–258 (2011)
   Google Scholar
• Evidence from laboratory, epidemiological and clinical trial studies is summarized that indicates that apoB is superior to any of the cholesterol indices for recognizing those at increased risk of vascular disease and judging the adequacy of lipid?lowering therapy.
   Google Scholar
• Brunzell JD, Davidson M, Furberg CD et al.: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31, 811–822 (2008)
   Google Scholar
• The American Diabetes Association (ADA) and American College of Cardiology (ACC) are the first two major scientific organizations stating that apoB is the preferred target for LDL?lowering therapy. They recommend apoB targets of 90 and 80 mg/dl for high-risk and very-high-risk patients, respectively.
   Google Scholar
• McPherson R, Frohlich J, Fodor J et al.: Canadian Cardiovascular Society position statement – recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can. J. Cardiol. 22, 913–927 (2011).
   Google Scholar
• Genest J, McPherson R, Frohlich J et al.: 2011 Canadian Cardiovascular Society/ Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2011 recommendations. Can. J. Cardiol. 25, 567–579 (2011).
   Google Scholar
• Vaverková H, Soska V, Rosolová H et al.: Czech Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias in adults (doporu?enĉ pro diagnostiku a lé?bu dyslipidemiĉ v dosp?losti, vypracovan’ vä;borem ?esl’ spole?nosti pro aterosklerézu). Vnitr. Lek. 53(2), 181–187 (2007).
   Google Scholar
• Sniderman A: Targets for LDL?lowering therapy. Curr. Opin. Lipidol. 20, 282–287 (2011)
   Google Scholar
• Compares non-HDL?C and apoB as targets for LDL?lowering therapy and evaluates which marker better identifies residual risk after any particular treatment regimen. In this regard, apoB clearly outperforms non-HDL?C.
   Google Scholar
• Stein EA, Sniderman A, Laskarzewski P: Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am. J. Cardiol. 96(Suppl.), 36K–43K (2005)
   Google Scholar
• Reviews the use of three biomarkers (LDL-C, non-HDL-C and apoB) in assessing cardiovascular risk and the strategies for managing combined hyperlipidemia.
   Google Scholar
• Vaverkova V, Frohlich J, Jackuliakova D et al.: Comparison of apolipoprotein B and plasma lipids as targets for lipid lowering treatment. Clin. Biochem. 38, 509–513 (2005)
   Google Scholar
• First study demonstrate that a large percentage of patients with hypertriglyceridemia or impaired glucose tolerance, when treated with lipid-lowering agents, reach the LDL?C but not the apoB treatment targets.
   Google Scholar
• Ballantyne CM, Raichlen JS, Cain VA: Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients. The MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy II) trial. J. Am. Coll. Cardiol. 52, 626–632 (2008)
   Google Scholar
• Presents the results from Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY) II study indicating that reducing LDL?C to a predetermined goal may still leave an excess of atherogenic lipoproteins, as reflected in apoB levels. According to the authors’ opinions, the tight correlation seen for non-HDL?C with apoB while on statin therapy implies that non-HDL?C may be an acceptable surrogate for direct apoB measurement. Nevertheless, good correlation between two parameters does not mean that they represent the same risk and may be of limited clinical value.
   Google Scholar
• Brudi P, Vaverkova H, Farnier M et al.: Switching from statin monotherapy to EZE/simva or rosuva modifies apo B, LDL?C, and non-HDL?C correlations in patients at high risk of coronary disease [abstract]. J. Clin. Lipidol. 4, 205 (2010).
   Google Scholar
• Bayturan O, Kapadia S, Nicholls SJ et al.: Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J. Am. Coll. Cardiol. 55, 2736–2742 (2010).
   Google Scholar
• Contois JH, McNamara JR, Lammi-Keefe CJ et al.: Reference intervals for plasma apolipoprotin B determined with a standardized commercial immunoturbidometric assay: results from the Framingham Offspring Study. Clin. Chem. 42, 515–523 (1996).
   Google Scholar
• Farnier M, Averna M, Missault L et al.: Lipid-altering efficacy of ezetimibe/ simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolemic patients inadequately controlled with prior statin monotherapy – the IN-CROSS study. Int. J. Clin. Pract. 63, 547–558 (2011).
   Google Scholar
• Sattar N, Williams K, Sniderman AD et al.: Comparison of the associations of apoB and non-HDL cholesterol with other cardiovascular risk factors in patients with metabolic syndrome in the Insulin Resistance Study (IRAS). Circulation 110, 2687–2693 (2004)
   Google Scholar
• Demonstrates that apoB is more tightly correlated with markers of insulin resistance than non-HDL?C.
   Google Scholar
• Vaverkova H, Karasek D, Novotny D et al.: Apolipoprotein B versus LDL?cholesterol: association with other risk factors for atherosclerosis. Clin. Biochem. 42, 1246–1251 (2011)
   Google Scholar
• Demonstrates that individuals with apoB levels higher than that predicted by their LDL?C levels are more insulin resistant and have worse atherogenic risk profiles. Thus, at least for dyslipidemic patients with high cardiometabolic risk, apoB is a more appropriate marker of risk than LDL?C.
   Google Scholar
• Marcovina SM, Albers JJ, Kennedy H et al.: International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material. Clin. Chem. 40, 586–592 (1994).
   Google Scholar
• Marcovina SM, Albers JJ, Henderson LO et al. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin. Chem. 39, 773–781 (1993).
   Google Scholar
• Miller M, Cannon CP, Murphy SA et al.: Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol. 51, 724–730 (2008).
   Google Scholar
• Di Angelantonio E, Sarwar N, Perry P et al.: Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993–2000 (2011).
   Google Scholar
• Barter PJ, Gotto AM, LaRosa JC et al.; for Treating to New Targets Investigators: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357, 1301–1310 (2007).
   Google Scholar
• Yusuf S, Hawken S, Ounpuu S et al.; for the INTERHEART Study Investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study). Lancet 364, 937–952 (2004).
   Google Scholar
• Sniderman AD, de Graaf J, Couture P et al.: Regulation of plasma LDL: the apoB paradigm. Clin. Sci. 118, 333–339 (2010)
   Google Scholar
• The ‘apoB paradigm’ states that the rate at which LDL particles are produced is at least as important a determinant of their concentration in plasma as the rate at which they are cleared from plasma, and that secretion of cholesterol within VLDL particles is an important mechanism of maintaining cholesterol homoeostasis within the hepatocyte.
   Google Scholar
• Davidson MH: Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr. Atheroscler. Rep. 11, 67–70 (2011).
   Google Scholar